Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial

Daunorubicin pharmacokinetics (PK) are characterised by an important inter-individual variability, which raises questions about the optimal dose regimen in patients with acute myeloid leukaemia. The aim of the study is to assess the joint daunorubicin/daunorubicinol PK profile and to define an optim...

Descripción completa

Detalles Bibliográficos
Autores principales: Drevin, Guillaume, Briet, Marie, Bazzoli, Caroline, Gyan, Emmanuel, Schmidt, Aline, Dombret, Hervé, Orvain, Corentin, Giltat, Aurelien, Recher, Christian, Ifrah, Norbert, Guardiola, Philippe, Hunault-Berger, Mathilde, Abbara, Chadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029035/
https://www.ncbi.nlm.nih.gov/pubmed/35456626
http://dx.doi.org/10.3390/pharmaceutics14040792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029035/
https://www.ncbi.nlm.nih.gov/pubmed/35456626
http://dx.doi.org/10.3390/pharmaceutics14040792

Ejemplares similares